International Journal of Multiphysics
Volume 18, No. 3, 2024
ISSN: 1750-9548

Effect of Dexmedetomidine on Postoperative Analgesia after laparoscopic cholecystectomy

Mohamed Ali Salama, Zeinab Ibrahim Ahmed El-Hossary, Salwa Hassan Waly and Hatem Ahmed Nazmy

Anesthesia, Intensive Care and Pain Management Department, Faculty of Medicine, Zagazig University, Egypt

***Corresponding author:** Mohamed Ali Salama

Email: mohamed.salama1881997@gmail.com,

Abstract:

Background: Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that provides sedation, analgesia, and sympatholysis without causing significant respiratory depression. It has gained increasing attention in anesthetic practice due to its opioid-sparing effect and its role in improving postoperative pain control. In laparoscopic cholecystectomy, where postoperative pain and hemodynamic fluctuations are common, the use of intravenous dexmedetomidine may enhance analgesic outcomes and stabilize intraoperative hemodynamics.

Keywords: Dexmedetomidine; Postoperative analgesia; Laparoscopic cholecystectomy; Opioid-sparing effect; Sedation; α2-adrenergic agonist

Introduction:

Dexmedetomidine, a highly selective alpha-2 adrenergic receptor agonist, has a relatively recent yet impactful history in anesthesiology and critical care. It was first synthesized in the late 1980s as a more selective analogue of clonidine, aiming to provide sedation and analgesia with fewer cardiovascular side effects **(1).**

The U.S. Food and Drug Administration (FDA) approved dexmedetomidine in 1999 for sedation of initially intubated and mechanically ventilated patients in the intensive care unit (ICU) (Hospira Inc., 1999). Its indication was later extended in 2008 to include sedation for non-intubated patients undergoing surgical or other procedures. Over the years, dexmedetomidine has gained popularity due to its ability to provide cooperative sedation without significant respiratory depression, its opioid-sparing properties, and potential neuroprotective effects **(2).** These characteristics have led to its use beyond ICU sedation, including as an adjunct in general and regional anesthesia and in postoperative pain control, representing a major advancement in sedative pharmacotherapy.

Chemical structure and classification:

Dexmedetomidine is structurally classified as an imidazole derivative. Figure 1 Chemically, it is identified as *(S)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole*, with the molecular formula a molecular weight of approximately 200.28 g/mol. The compound consists of an imidazole ring attached to a chiral ethyl group, which is further linked to a 2,3-dimethylphenyl moiety. Its stereochemistry is crucial to its pharmacological activity, as dexmedetomidine represents the active S-enantiomer of medetomidine, responsible for its high affinity and

selectivity towards alpha-2 adrenergic receptors. The structural specificity contributes to its sedative, analgesic, and sympatholytic effects, distinguishing it from racemic or less selective analogs **(3).**



Figure (1): Dexmedetomidine structural formula **(4)**

Mechanism of Action:

Widely utilized in both anesthesia and critical care, dexmedetomidine is a potent and highly selective agonist of the α2-adrenergic receptor as shown in figure 2, known for its multifaceted pharmacological profile, including sedative, analgesic, anxiolytic, and sympatholytic effects. Its mechanism of action centers on the activation of α2A-receptors, particularly in the locus coeruleus of the brainstem, which facilitates sedation, and in the dorsal horn of the spinal cord, where it contributes to analgesia. In contrast to agents like benzodiazepines and propofol that exert their effects via GABAergic transmission, dexmedetomidine engages endogenous neural pathways associated with sleep, leading to a sedation state that closely resembles physiological sleep **(5)**. Additionally, by inhibiting norepinephrine release through central α2-receptor stimulation as shown in figure 3, it significantly reduces sympathetic nervous system activity, thereby promoting bradycardia and hypotension—hallmarks of its sympatholytic action **(1).**



Figure (2): Visual representation of dexmedetomidine mechanism of action **(2)**



Figure (3): Action of dexmedetomidine on α2-adrenergic receptor **(6)**

The α2 adrenoceptor agonists produce clinical effects after binding to G-Protein-coupled α2-AR, of which there are three subtypes (α2A, α2B, and α2C) with each having different physiological functions and pharmacological activities (Table 1). These receptor subtypes are found ubiquitously in the central, peripheral, and autonomic nervous systems, as well as in vital organs and blood vessels. Dexmedetomidine is 8 to 10 times more selective towards α2-AR than clonidine. Neither clonidine nor dexmedetomidine is totally selective for any one of the α2-AR subtypes, but dexmedetomidine seems to have higher α2A-AR and α2C-AR affinity than clonidine. Locus coeruleus of the brain stem is the principal site for the sedative action and spinal cord is the principal site for the analgesic action, both acting through α2A-AR **(7).**

Table (1): Summary of alpha2 receptor subtypes and effects **(8)**

Location of the receptor	Subtype of the receptor	Stimulation or inhibition	Effect
Dorsal horn of the spinal cord	α2C and α2A	Stimulation	Reduced release of substance P and glutamate—leads to analgesia
Unmyelinated C-fibers		Hyperpolarization	Prolongation of sensory blockade
Prejunctional and postjunctional Vascular smooth muscle	α2A and α2B	Stimulation	Initial increase in arterial blood pressure, decreased heart rate, decreased blood pressure
Central nervous system locus coeruleus	α2C and α2A	Stimulation	Sedation, hypnosis

Pharmacokinetics:

Dexmedetomidine is typically administered intravenously due to poor oral bioavailability. Following IV administration, it demonstrates a rapid distribution phase with a distribution half-life of approximately 6 minutes. Its volume of distribution ranges between 1.3 and 2.5 L/kg, suggesting extensive tissue penetration **(9).** The elimination half-life is relatively short, averaging 2 to 3 hours in healthy adults, which allows for flexible titration during both short procedures and longer infusions in intensive care settings. Steady-state concentrations can typically be achieved within 30 to 60 minutes depending on the infusion rate and presence of a loading dose (**10**).

Metabolism and Clearance:

Dexmedetomidine is predominantly metabolized in the liver through two primary pathways: direct glucuronidation, mainly via the UGT1A4 and UGT2B10 enzymes, and oxidative biotransformation mediated by cytochrome P450 isoenzymes, with CYP2A6 playing a central role **(9).** The drug exhibits a high degree of plasma protein binding, approximately 94%, which influences its distribution and clearance. In healthy individuals, systemic clearance is relatively rapid, averaging about 39 liters per hour. Elimination occurs primarily through renal pathways, with nearly 95% of its metabolites excreted in the urine, while the unchanged drug accounts for less than 1% of excretion **(11).** However, in the presence of hepatic dysfunction, the metabolism of dexmedetomidine is markedly reduced, highlighting the need for careful dose modification in patients with impaired liver function (**10**).

Dosage and Administration:

Intramuscular: 2.5 mcg/kg of dexmedetomidine has been used for premedication.

Intravenous: loading dose of 1 mcg/kg over 10-20 minutes followed by a maintenance infusion in the range of 0.2- 0.7 mcg/kg/hr. The rate of infusion can be increased or titrated up to 1.5 mcg/kg/hr.

Spinal: 0.1-0.2 mcg/kg.

Epidural: 1-2 mcg/kg.

Peripheral nerve block: 1 mcg/kg.

Buccal: 1-2 mcg/kg.

Intranasal: 1-2mcg/kg (Naaz & Ozair, 2014).

Clinical Benefits and Applications:

In contemporary anesthesia practice, dexmedetomidine is recognized for its broad spectrum of clinical benefits. One of its most significant advantages is the ability to provide reliable sedation while preserving respiratory function, making it particularly suitable for procedures involving conscious sedation and for facilitating smooth extubation **(1).** Beyond its sedative action, dexmedetomidine plays a crucial role in reducing opioid consumption, both intraoperatively and postoperatively. This opioid-sparing effect helps to limit common opioid-related complications, including respiratory depression, nausea, and gastrointestinal dysmotility **(12).** In surgeries such as laparoscopic cholecystectomy, the drug contributes to enhanced hemodynamic control by

blunting the sympathetic response to pneumoperitoneum and surgical stress, thereby lowering overall anesthetic requirements (**13**).

Additionally, in intensive care settings, dexmedetomidine has demonstrated superiority over benzodiazepines by reducing the incidence of delirium and shortening the duration of mechanical ventilation (**14).**

Procedural sedation: Dexmedetomidine is a sedative drug that is indicated for the sedation of non-intubated patients prior to and/or during surgical and other procedures (**15**). It has been safely used in various procedures such as trans esophageal echocardiography, colonoscopy, awake carotid end arterectomy, shockwave lithotripsy, vitreoretinal surgery, and pediatric tonsillectomy. The usual dose of dexmedetomidine for procedural sedation is 1μg/kg, followed by an infusion of 0.2μg/kg. Its onset of action is less than 5 minutes, and the peak effect occurs within 15 minutes (**16**).

Dexmedetomidine, due to its high lipophilicity, is rapidly absorbed into the cerebrospinal fluid, where it binds to spinal alpha2-A adrenergic receptors to exert its analgesic effects. As an adjuvant in local and regional anesthesia techniques, it significantly enhances the efficacy of local anesthetics. It has been shown to prolong both sensory and motor blockade, regardless of the administration route—be it spinal, epidural, or caudal. Moreover, dexmedetomidine augments the effects of local anesthetics at both central and peripheral levels and has demonstrated successful application in intravenous regional anesthesia (IVRA). When added to lidocaine at a dose of 0.5 μg/kg for IVRA, it improves the quality of anesthesia and extends both intraoperative and postoperative analgesia without inducing adverse effects (**17**).

Clinical trials have consistently shown that dexmedetomidine possesses significant opioid-sparing properties. It has also demonstrated efficacy as a standalone analgesic; for example, a dose of 0.4 μg/kg has been found effective in managing postoperative pain following laparoscopic tubal ligation. However, its use may be limited by side effects such as drowsiness and bradycardia during the recovery phase (**18)**

When administered intraoperatively during general anesthesia, dexmedetomidine has been shown to outperform remifentanil in terms of postoperative pain control. Patients receiving dexmedetomidine reported lower pain scores within the first 24 hours post-surgery, as well as reduced incidences of hypotension, shivering, and postoperative nausea and vomiting (**19**).

Dexmedetomidine also exhibits antinociceptive properties against both somatic and visceral pain when used via the neuraxial route. Its neuraxial administration has been associated with decreased postoperative pain intensity and prolonged analgesia, albeit with a higher likelihood of inducing bradycardia (**20**)

Research has further explored dexmedetomidine's potential in managing neuropathic pain. Local administration has shown antiallodynic effects in models of spinal nerve ligation-induced neuropathy. Additionally, pre-emptive intravenous use has been linked to a reduction in post-thoracotomy pain syndrome in patients undergoing coronary artery bypass grafting (**21, 22**).

Adverse Effects and Safety Profile:

Common Adverse Effects:

Although dexmedetomidine offers numerous therapeutic advantages, its side effect profile—especially regarding cardiovascular function—warrants careful consideration. Bradycardia and hypotension are the most commonly reported adverse events, primarily attributed to the drug's potent central sympatholytic effects and peripheral vasodilatory action. These effects are dose-dependent and may become clinically significant, particularly in patients with pre-existing conduction system abnormalities, baseline bradycardia, or hypovolemia. In such cases, significant bradyarrhythmias or hypotensive episodes may require pharmacologic support or discontinuation of the infusion **(23).**

Withdrawal and Rebound Effects:

Furthermore, rapid cessation after prolonged administration can lead to rebound hypertension due to sudden withdrawal of α2-adrenergic receptor stimulation, resulting in a surge of sympathetic tone. This phenomenon is particularly concerning in hemodynamically unstable or hypertensive patients, and gradual weaning of the drug is recommended to mitigate the risk (**10**).

Other Side Effects:

Additional adverse effects, though less frequently encountered, include dry mouth, nausea, and rarely, paradoxical agitation or transient hypertension during the initial loading phase. Moreover, the risk of hemodynamic disturbances can be compounded by the use of concurrent medications. Drugs such as beta-blockers, calcium channel blockers, or other sedatives may potentiate dexmedetomidine's bradycardic and hypotensive effects, necessitating close cardiovascular monitoring during administration. Thus, while dexmedetomidine is generally well tolerated and effective, individualized dosing strategies and vigilant patient monitoring are essential, particularly in high-risk populations or during prolonged infusions (**9**).

Toxicity Profile:

Mild Toxicity

At low supratherapeutic levels, dexmedetomidine may cause mild adverse effects such as sedation beyond the desired level, dry mouth, and mild bradycardia, without significant hemodynamic instability. These effects are typically dose-dependent and reversible upon discontinuation of the drug. Mild oversedation may also result in delayed emergence from anesthesia, particularly when dexmedetomidine is used in combination with other sedatives (**24**). These side effects are generally manageable and rarely require intervention.

Moderate Toxicity

Moderate toxicity is characterized by clinically significant bradycardia and hypotension, which may necessitate pharmacological intervention such as atropine or vasopressors. These effects are more common in patients with pre-existing cardiovascular disease or when high infusion rates are used for prolonged periods. In some studies, moderate hypotension occurred at infusion rates above the recommended 0.7 μg/kg/h, even within

approved dosing windows .Although usually manageable, these symptoms require careful hemodynamic monitoring, especially in high-risk populations (**25**).

Severe Toxicity

Severe toxicity is rare but has been reported in cases of overdose or prolonged high-dose infusions. It can include profound bradycardia, sinus arrest, cardiac arrest, and severe hypotension. In one study, high plasma concentrations of dexmedetomidine (above 4.0 ng/mL) were associated with significant cardiac depression (**23**).

Another report documented complete sinus arrest in a healthy volunteer, indicating that even individuals without known comorbidities may be at risk when exposed to excessive doses (**26**).

Special Populations and Considerations:

Dexmedetomidine's unique pharmacodynamic and pharmacokinetic characteristics render it highly adaptable for use across diverse clinical populations, including elderly individuals, pediatric patients, and those with compromised respiratory function. Its minimal impact on ventilatory drive makes it particularly advantageous in patients at risk for respiratory depression, such as individuals with obstructive sleep apnea or chronic obstructive pulmonary disease (COPD). Moreover, due to its sedative profile mimicking natural sleep and its opioid-sparing effects, dexmedetomidine is frequently preferred in populations vulnerable to opioid-related adverse effects, including the elderly and critically ill. (**1**).

Despite its broad applicability, the use of dexmedetomidine must be approached with caution in patients with hepatic impairment. Because the drug undergoes extensive hepatic metabolism via glucuronidation and cytochrome P450 enzymes, impaired liver function can significantly delay its clearance, leading to prolonged sedation and increased susceptibility to side effects such as hypotension and bradycardia (**9**).

In such cases, dosage reductions and close monitoring are essential to avoid accumulation and toxicity. Renal impairment, in contrast, does not appear to significantly affect dexmedetomidine pharmacokinetics, as the parent compound is minimally excreted unchanged in urine (**11).**

Drug Interactions:

Drug interactions are another important consideration. Co-administration of dexmedetomidine with other sedatives, anesthetics, antihypertensive agents, or negative chronotropic drugs (e.g., beta-blockers) can potentiate both sedative depth and cardiovascular depression. This necessitates a tailored approach to dosing and vigilant intraoperative monitoring to ensure hemodynamic stability and avoid synergistic adverse effects (**10**).

Use in Total Intravenous Anesthesia (TIVA):

In the setting of total intravenous anesthesia (TIVA), dexmedetomidine is commonly used as an adjunct to agents such as propofol and ketamine. When used in combination, dexmedetomidine contributes to a balanced anesthetic technique by enhancing analgesia, reducing the required dose of hypnotic agents, and mitigating the sympathetic response to surgical stimuli (**27**).

For instance, the combination of dexmedetomidine with propofol may provide improved sedation quality while preserving hemodynamic control and reducing postoperative nausea and vomiting **(28).**

When paired with ketamine, dexmedetomidine can counteract ketamine-induced sympathomimetic effects and emergence phenomena, offering a complementary pharmacological profile (**29).**

These multimodal strategies are especially beneficial in ambulatory or minimally invasive surgeries such as laparoscopic cholecystectomy, where rapid recovery and precise anesthetic titration are key goals (**30).**

References:

1. Kamibayashi, T., & Maze, M. (2000). Clinical uses of alpha2-adrenergic agonists. Anesthesiology, 93(5), 1345–1349. https://doi.org/10.1097/00000542-200011000-00038
2. Su, F., & Hammer, G. B. (2016). Dexmedetomidine: Pediatric Pharmacology, Clinical Uses and Safety. Expert Opinion on Drug Safety, 15(11), 1491–1502. https://doi.org/10.1080/14740338.2016.1230356
3. Scheinin, M., Virtanen, R., MacDonald, E., & Lammintausta, R. (1992). Medetomidine—a novel alpha 2-adrenoceptor agonist: Pharmacological studies. Acta Veterinaria Scandinavica. Supplementum, 85, 29–37.
4. Wang, W., Huo, P., Wang, E., Song, W., Huang, Y., Liu, Z., Zhao, B., & Xia, Z. (2022). Dexmedetomidine infusion for emergence coughing prevention in patients undergoing an endovascular interventional procedure: A randomized dose-finding trial. European Journal of Pharmaceutical Sciences, 177, 106230. https://doi.org/10.1016/j.ejps.2022.106230
5. Nelson, L. E., Lu, J., Guo, T., Saper, C. B., Franks, N. P., & Maze, M. (2003). The α2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology, 98(2), 428–436. https://doi.org/10.1097/00000542-200302000-00024
6. Bargnes, V., Oliver, B., Wang, E., & Bergese, S. (2023). Taming postoperative delirium with dexmedetomidine: A review of the therapeutic agent's neuroprotective effects following surgery. Journal of [Neuroprotective Effects].
7. Lechsner, P., & Ban, E.-G. (2022). Alpha adrenergic receptors in clinical practice–Present and future. Acta Marisiensis-Seria Medica, 68(4), 145-49.
8. Rao, S., & Rajan, N. (2021). Dexmedetomidine as an Adjunct for Regional Anesthetic Nerve Blocks. Current pain and headache reports, 25(2), 8.
9. Weerink, M. A. S., Struys, M. M. R. F., Hannivoort, L. N., Barends, C. R. M., Absalom, A. R., & Colin, P. J. (2017). Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clinical Pharmacokinetics, 56(8), 893–913. https://doi.org/10.1007/s40262-017-0507-7
10. Bhana, N., Goa, K. L., McClellan, K. J. (2000). Dexmedetomidine. Drugs, 59(2), 263–268. https://doi.org/10.2165/00003495-200059020-00010
11. Karol, M. D., Maze, M., & Maze, M. (2009). Pharmacokinetics and metabolism of dexmedetomidine. In: Pharmacology of Sedative-Hypnotics.
12. Bajwa, S. J. S., Kaur, J., Singh, A., Parmar, S. S., Singh, G., & Kulshrestha , A. (2012). Attenuation of pressor response and dose sparing of opioids and anaesthetics with pre-operative dexmedetomidine. Indian Journal of Anaesthesia, 56(2), 123–128. https://doi.org/10.4103/0019-5049.96302
13. Talke, P., Chen, R., Thomas, B., Aggarwall, A., & Gottlieb, A. (2000). The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesthesia &

Analgesia, 90(4), 834–839. https://doi.org/10.1097/00000539-200004000-00016

14. Pandharipande, P. P., Pun, B. T., Herr, D. L., Maze, M., Girard, T. D., Miller, R. R., ... & Ely, E. W. (2007). Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA, 298(22), 2644–2653. https://doi.org/10.1001/jama.298.22.2644
15. Naaz S, and Ozair E (2014). Dexmedetomidine in current anaesthesia practice-a review. Journal of clinical and diagnostic research: JCDR, 8(10):1-4.
16. Kaur, M., & Singh, P. M. (2011). Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesthesia, Essays and Researches, 5(2), 128.
17. Tang, C., & Xia, Z. (2017). Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. Journal of pain research, 1899-1904.
18. Aho, M. S., Erkola, O. A., Scheinin, H., Lehtinen, A. M., & Korttila, K. T. (1991). Effect of intravenously administered dexmedetomidine on pain after laparoscopic tubal ligation. Anesthesia & Analgesia, 73(2), 112–118. https://doi.org/10.1213/00000539-199108000-00002
19. Zhao, Y., He, J., Yu, N., Jia, C., & Wang, S. (2020). Mechanisms of dexmedetomidine in neuropathic pain. Frontiers in Neuroscience, 14, 330.
20. Bi, Y.-H., Cui, X.-G., Zhang, R.-Q., Song, C.-Y., & Zhang, Y.-Z. (2020). Effect of different doses of intrathecal dexmedetomidine as an adjuvant combined with hyperbaric ropivacaine in patients undergoing cesarean section. Frontiers in Pharmacology, 11, 342. https://doi.org/10.3389/fphar.2020.00342
21. Cheng, X.-q., Cheng, J., Zhou, Y.-n., Zuo, Y.-m., Liu, X.-s., et al. (2021). Anti-nociceptive effects of dexmedetomidine infusion plus modified intercostal nerve block during single-port thoracoscopic lobectomy: a double-blind, randomized controlled trial. Pain Physician, 24(5), 565-72.
22. Pratiwi, D. A. N. I., Sucandra, I. M. A. K., & Senapathi, T. G. A. (2021). Dexmedetomidine versus clonidine as adjuvants in epidural analgesia in gynecological laparotomy: Case series. Bali Journal of Anesthesiology, 5(1), 33-37.
23. Snapir, A., Posti, J., Kentala, E., Koskenvuo, J., Sundell, J., Tuominen, J., ... & Scheinin, M. (2006). Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology, 105(5), 902–910. https://doi.org/10.1097/00000542-200611000-00013
24. Arain, S. R., & Ebert, T. J. (2002). The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesthesia & Analgesia, 95(2), 461–466. https://doi.org/10.1097/00000539-200208000-00041
25. Venn, R. M., Bryant, A., Hall, G. M., & Grounds, R. M. (2000). Effects of dexmedetomidine on cardiovascular stability when used as a sedative agent in critically ill patients. British Journal of Anaesthesia, 84(6), 794–800. https://doi.org/10.1093/oxfordjournals.bja.a013578
26. Ebert, T. J., Hall, J. E., Barney, J. A., Uhrich, T. D., & Colinco, M. D. (2000). The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology, 93(2), 382–394. https://doi.org/10.1097/00000542-200008000-00024

27. Tufanogullari, B., White, P. F., Peixoto, M. P., Zheng, D., Rosero, E. B., & Yumul, R. (2008). Dexmedetomidine infusion during laparoscopic bariatric surgery: The effect on recovery outcome variables. Anesthesia & Analgesia, 106(6), 1741–1748. https://doi.org/10.1213/ane.0b013e318173f612
28. Pratiwi, D. A. N. I., Sucandra, I. M. A. K., & Senapathi, T. G. A. (2021). Dexmedetomidine versus clonidine as adjuvants in epidural analgesia in gynecological laparotomy: Case series. Bali Journal of Anesthesiology, 5(1), 33-37.
29. Mercanoglu, E. E., Girgin Kelebek, N., Türker, G., Aksu, H., Ozgür, M., Karakuzu, Z., et al.(2022). Comparison of the effect of ketamine and dexmedetomidine combined with total intravenous anesthesia in laparoscopic cholecystectomy procedures: A prospective randomized controlled study. International Journal of Clinical Practice, 2022, Article 1878705. https://doi.org/10.1155/2022/1878705
30. White, P. F., Tang, J., & Wender, R. H. (2009). Dexmedetomidine as an adjuvant to propofol-based intravenous anesthesia for outpatient procedures. Current Opinion in Anesthesiology, 22(4), 481–485. https://doi.org/10.1097/ACO.0b013e32832c405